From:  Exploring new pathways in endocrine-resistant breast cancer

Alterations in Notch pathway according to BC subtype [165]

SubtypeBC subtype
HER2+Basal-likeLuminal ALuminal B
Notch activation (mRNA, protein)

  • - High Notch2 expression

  • - Notch4 expression positively correlates with ER positivity

  • - Notch1 expression inversely correlates with HER2 expression

  • - Absence of ER expression correlates with higher Notch3 expression

  • - Notch1 expression inversely correlates with ER and PR expression

  • - High Notch2 expression

  • - TNBCs highly express Notch1–3

  • - Absence of ER expression correlates with higher Notch3 expression

  • - Notch1 expression in 100% of TNBCs assessed

  • - Notch4 expression in 73% of TNBCs assessed

  • - Low Notch3 expression in TNBC compared to luminal A tumors

  • - Notch1 enriched in the basal subtype

  • - High Notch2 expression

  • - Notch4 expression positively correlates with ER positivity

  • - Notch1 expression inversely correlates with HER2 expression

  • - High Notch3 expression compared to TNBC

  • - Notch1 expression inversely correlates with ER and PR expression

  • - High Notch2 expression

  • - Notch4 expression positively correlates with ER positivity

  • - Notch1 expression inversely correlates with HER2 expression

  • - Notch1 expression inversely correlates with ER and PR expression

Return to article view

Note. Adapted from “Moving breast cancer therapy up a notch,” by Mollen EWJ, Ient J, Tjan-Heijnen VCG, Boersma LJ, Miele L, Smidt ML, et al. Front Oncol. 2018;8:518 (https://www.frontiersin.org/articles/10.3389/fonc.2018.00518/full). CC BY.